Appendix 4C - Q4 FY22 Quarterly Cash Flow Report Phase 2 clinical trial for ATH434 commences in New Zealand and patient enrolment begins Regulatory approval from the U.K. and Italian regulatory agencies to proceed with t

4C - Q4 FY22 Quarterly Cash Flow Report

AUSTRALIA AND SAN FRANCISCO, USA - 22 July 2022. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity"

or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases,

releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30th June 2022

Company's cash position at 30 June 2022 was A$34.8M with gross operating cash outflows of A$4.4M, which are aligned with Alterity's

expectations as its progresses and expands its Phase 2 clinical trial of lead drug candidate ATH434 for the treatment of Multiple System

Atrophy (MSA), a rare Parkinsonian disorder with no approved therapy.

its cash position during the quarter, Alterity received a A$4.1 million refund from the Australian Taxation Office under the Australian

Government's R&D Tax Incentive Scheme which will be used to further its research and development activities.

accordance with ASX Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of the Appendix 4C

incorporates directors' fees, consulting fees, remuneration and superannuation at commercial rates.

a milestone clinical achievement, Alterity commenced its Phase 2 clinical trial for ATH434 during the quarter with the dosing of the

first patient at its first global site at New Zealand's Brain Research Institute (NZBRI).

randomized, double-blind, placebo-controlled study will enrol approximately 60 adult patients who will receive two dose levels of ATH434

or the placebo over a period of 12 months. Results will provide an opportunity to detect changes in efficacy endpoints to optimize design

of a definitive Phase 3 study.

of the Phase 2 clinical trial is a significant achievement for the Company and the industry as Alterity progresses through its clinical

pipeline aiming to bring the first known therapy for MSA to market.

Company also received regulatory approval from the Italian Medicines Agency, or Agenzia Italiana del Farmaco (AIFA) to expand recruitment

and clinical sites into Italy. This follows receipt of approval from the United Kingdom Medicines & Healthcare products Regulatory

Agency (MHRA). The company is working closely with clinical sites in these countries to initiate patient recruitment.

also plans to further expand its Phase 2 trial into other European countries, Australia, and the United States and is exploring the addition

of new drug candidates that address neurodegenerative disorders to its growing portfolio pipeline.

continues to create awareness on the Company's work to develop therapeutic solutions for neurodegenerative diseases. Communication

activities to investors, clinicians and patients ramped up during the quarter with greater engagement of the media to support awareness

and recruitment of the Phase 2 clinical trials.

part of the Company's wider exposure strategy, Chief Executive Officer David Stamler, M.D., presented at three investor focused

events. Dr. Stamler was invited to participate in the Benchmark Company Healthcare House Call Conference, having the opportunity to introduce

Alterity to Benchmark's clients in the US and beyond. He also presented at the VirtualInvestorConferences.com Life Sciences Investor

Forum and at the Global Chinese Financial Forum (GCFF) Virtual Conference 2022 - Investing in Healthcare Conference.

further support for Alterity's profile with clinicians and patient groups, a poster session was delivered on the Biomarkers of

progression in Multiple System Atrophy (bioMUSE) study at the American Academy of Neurology (AAN) Annual Meeting in April.

Stamler, CEO said: "We are delighted to see all the work we put into the progress of our Phase 2 clinical study coming to fruition

with the start of recruitment in New Zealand. We are partnering with leading research institutions, clinicians, and scientists from around

the globe to reach our goal of finding a treatment that can improve the lives of patients with MSA, and potentially reversing the grim

outlook they face when receiving this diagnosis."

June, Alterity secured a patent (16/311,428) from the US Patent and Trademark Office on the method of treating immunoglobulin light chain

amyloidosis, a rare blood disorder caused by the overproduction of abnormal protein known as amyloid.

lead candidate, ATH434, is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins

implicated in neurodegeneration. ATH434 has been shown preclinically to reduce -synuclein pathology and preserve nerve cells by

restoring normal iron balance in the brain. In this way, it has excellent potential to treat Parkinson's disease as well as various

forms of atypical Parkinsonism such as Multiple System Atrophy (MSA). ATH434 has successfully completed a Phase 1 clinical trial demonstrating

the agent is well tolerated, orally bioavailable, and achieved brain levels comparable to efficacious levels in animal models of MSA,

with the objective of restoring function in patients with MSA and other Parkinsonian disorders. ATH434 has been granted Orphan designation

for the treatment of MSA by the U.S. FDA and the European Commission. ATH434 is currently in a randomized, double-blind, placebo-controlled

Phase 2 clinical trial of ATH434 in patients with early-stage MSA.

Multiple System Atrophy

System Atrophy (MSA) is a rare, neurodegenerative disease characterized by a combination of symptoms that affect both the autonomic

nervous system and movement. The symptoms reflect the progressive loss of function and death of different types of nerve cells in

the brain and spinal cord. It is a rapidly progressive disease and causes profound disability. MSA is a Parkinsonian disorder

characterized by motor impairment, autonomic instability that affects involuntary functions such as blood pressure maintenance and

bladder control, and impaired balance and/or coordination that predisposes to falls. A pathological hallmark of MSA is the

accumulation of the protein -synuclein within the support cells of the central nervous system and neuron loss in multiple

brain regions. MSA affects approximately 15,000 individuals in the U.S., and while some of the symptoms of MSA can be treated with

medications, currently there are no drugs that are able to slow disease progression and there is no cure.1

Alterity Therapeutics Limited

Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative

diseases. The Company's lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad

drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne,

Australia, and San Francisco, California, USA. For further information please visit the Company's web site at www.alteritytherapeutics.com.

& Additional information

announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section

21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as

"expects," "intends," "hopes," "anticipates," "believes," "could," "may,"

"evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying

factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in

the sections titled "Risk Factors" in the Company's filings with the SEC, including its most recent Annual Report on

Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development

program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program,

including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties,

including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing,

regulatory approval, production and marketing of the Company's drug components, including, but not limited to, ATH434, uncertainties

relating to the impact of the novel coronavirus (COVID-19) pandemic on the company's business, operations and employees, the ability

of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy

of the Company's drug compounds, including, but not limited to, ATH434, that couldslow or prevent productscoming to market, the uncertaintyof

obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company's

patent rights and the uncertainty of the Company freedom to operate.

forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as

of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral,

that may be made from time to time, whether as a result of new information, future developments or otherwise.

cash flow report for entities subject to Listing Rule 4.7B

flow report for entities subject to Listing Rule 4.7B

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Quarterly cash flow report for entities subject to Listing Rule 4.7B